Q3 will be far greater..than the their latest quarter/Q2. Thats' a guarantee. For so many reasons. For instance, Flower 1.0 was nearly non-existent in Q2 - approx. 85% of their monies from cannabis 2.0. They now have Kolab Flower & Robinsons on this Q. Aside from that, an absolute abundance of new vape products introduced on the OCS (canada-wide too)..including award winning dosist/exclusive. Dosist has 14 or 15 different vapes under that brand alone; not including Kolab project and Foray. Then, theres' the-ever expanding distrubution most recently medical cannabis by shoppers. Their edibles gummies have taken off like a rocket too/ best sellers top-notch Quality and a wickedly improving order fullfillment rate all around. KGK science will @ least double their net revenue in contribution to a much improved quarter-over-quarter.
But Q4 will be !! that much more.